<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01678027</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS04-103</org_study_id>
    <nct_id>NCT01678027</nct_id>
  </id_info>
  <brief_title>Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication</brief_title>
  <official_title>Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate whether treatment of Helicobacter pylori infection reduces the incidence
      of gastric cancer in subjects with family history of gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori infection is associated with gastric cancer in epidemiological studies.
      However, it is still unknown whether H. pylori eradication is useful and required to prevent
      gastric cancer.

      Gastric cancer risk is increased in family members of gastric cancer patient. Though there is
      no direct evidence that H. pylori infection is a risk factor for gastric cancer in family
      members of gastric cancer, current European guideline recommends H. pylori eradication in
      first-degree relatives of gastric cancer patients.

      In this study, the investigators will evaluate whether H. pylori eradication can reduce
      gastric cancer risk in the first-degree family members of gastric cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric cancer incidence</measure>
    <time_frame>6 years after last participant enrollment</time_frame>
    <description>The incidence of gastric cancer will be compared between the two arms as the participant assigned into either LAC treatment group or placebo group regardless the final H. pylori infection status.
Currently, efficacy of LAC triple therapy shows about 75-85% eradication rate of the H. pylori.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric dysplasia incidence</measure>
    <time_frame>6 year after last participant enrollment</time_frame>
    <description>Incidence of gastric dysplasia according to the H. pylori treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric cancer incidence between H. pylori treatment and H. pylori uninfected groups</measure>
    <time_frame>6 year after last participant enrollment</time_frame>
    <description>Gastric cancer incidence between H. pylori treatment group and H. pylori uninfected group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric cancer incidence according to H. pylori status</measure>
    <time_frame>6 year after last participant enrollment</time_frame>
    <description>Gastric cancer incidence between H. pylori eradicated group and H. pylori persistent group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 year after last participant enrollment</time_frame>
    <description>All-cause mortality between H. pylori treatment group and placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1837</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Family Members</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for LAC triple therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAC triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPI (Lansoprazole), Clarithromycin, Amoxicilline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAC triple therapy</intervention_name>
    <description>Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.</description>
    <arm_group_label>LAC triple therapy</arm_group_label>
    <other_name>PPI-Clarithromycin containing triple therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sibling or offspring of patients with gastric adenocarcinoma confirmed by EGD and
             biopsy

          -  Informed consent should be signed

        Exclusion Criteria:

          -  Gastric cancer history

          -  Other malignancy within the past 5 years

          -  Hereditary cancer family member (HNPCC, FAP)

          -  Peptic ulcer history

          -  Peptic ulcer, esophageal cancer, gastric cancer case found at EGD

          -  H. pylori eradication treatment history

          -  Previous serious side effect to antibiotics

          -  Serious concurrent infection or nonmalignant disease such as liver cirrhosis, renal
             failure, cardiovascular diseases

          -  Pregnant or nursing women

          -  Psychiatric disorder that would preclude compliance, alcoholics

          -  Refuse informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2012</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Il Ju Choi</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>Stomach neoplasm</keyword>
  <keyword>Helicobacter pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

